This review (2015) examines Banisteriopsis caapi and its active alkaloid harmine as a potential therapy for Parkinson’s disease based on its unique pharmacological profile, which includes selective MAO type A inhibition, serotonin affinity, NMDA receptor
antagonism, and possible antioxidative and neuroprotective properties, and may also cause direct striatal dopamine release.
Movement Disorders Clinical Practice
October 2015
Cited by 13
This open-label pilot study (n=12) found that psilocybin therapy (10mg followed by 25mg dose with psychotherapy) for Parkinson's disease patients with depression and/or anxiety appeared safe with no serious adverse events, whilst showing promising improvements in motor symptoms, cognitive function, depression and anxiety that persisted at three-month follow-up.
Neuropsychopharmacology
April 2025
Cited by 0
This study (2010) shows evidence of the potential efficacy of ayahuasca in the treatment of Parkinson's disease. Several extracts are examined and scored according to the different (expected) effects.
Journal of Ethnopharmacology
February 2010
Cited by 136
This chemical profiling study investigated the different formulations of ayahuasca and proposes that the identified compounds can serve as reliable markets for the potency/composition of ayahuasca brews.
Journal of Ethnopharmacology
February 2010
Cited by 65
This animal study (n=8) investigated the efficacy of Banisteriopsis caapi (0.1 - 0.3 mg/kg harmine) alone and in combination with L‐DOPA (4 - 7 mg/kg) to treat parkinsonian dyskinesia in a marmoset disease model. B. caapi alone has a mild antiparkinsonian effect but does not enhance the L‐DOPA response or reduce dyskinesia.
Phytotherapy Research
January 2018
Cited by 8
This cross-species experimental study (n=21 humans; n=10 rats) finds that psilocin (18.2mg/70kg for humans; 0.3mg/kg for rats) impairs the ability to distinguish between static and moving images in both humans and rats. In humans, the impairment aligns with psilocin plasma levels and self-reported hallucination intensity. In rats, the effect is specific to motion perception, providing the first evidence of psilocin-induced visual distortions across species.
Biological Psychiatry
May 2025
Cited by 0
This review (2021) finds that psychedelics may act as modulators of the immune system by reducing levels of pro-inflammatory biomarkers. The early evidence points towards psychedelics also being effective in treating or preventing brain injury and neurodegenerative diseases (e.g. Alzheimer's Disease).
Journal of Neurochemistry
September 2021
Cited by 0
This phenomenological study (n=23) investigates DMT-induced immersive experiences and encounters with autonomous presences during fMRI scanning. Using micro-phenomenological interviews, it identifies structural features and temporal dynamics of DMT experiences, highlighting layered sensory, spatial, self-related, and social effects that extend beyond ego dissolution or mystical experiences.
Preprints
December 2024
Cited by 0
Find Psychedelic Papers
Find all relevant psychedelic research papers in our ever-growing database. Here we cover and connect the latest research and seminal papers. From early open-label psychedelic studies with healthy volunteers to large-scale double-blind, placebo-controlled trials.
We have not only indexed over 2000 papers but have added additional contexts such as type of study, a compound studied, which paper it’s related to, the trial associated with a study, and over 30 more variables.
More coverage of psychedelic research can be found on our Research page.
